Immunovant, Inc. Warrants expiring 12/18/2024
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
You can watch IMVTW and buy or sell other stocks, options, and ETFs commission-free!About IMVTW
Immunovant, Inc. is a clinical-stage biopharmaceutical company, which focuses on enabling normal lives for patients with autoimmune diseases. It is developing a novel, fully human monoclonal antibody IMVT-1401 that selectively binds to and inhibits the neonatal fragment crystallizable receptor.
CEOPeter Salzmann, MD, MBA
CEOPeter Salzmann, MD, MBA
Employees—
Employees—
HeadquartersNew York, New York
HeadquartersNew York, New York
Founded2018
Founded2018
Employees—
Employees—
IMVTW Key Statistics
Market cap—
Market cap—
Price-Earnings ratio—
Price-Earnings ratio—
Dividend yield—
Dividend yield—
Average volume—
Average volume—
High today—
High today—
Low today—
Low today—
Open price—
Open price—
Volume0.00
Volume0.00
52 Week high—
52 Week high—
52 Week low—
52 Week low—